A phase 1 single center, open label, fixed sequence, parallel group study evaluating pharmacokinetic drug-drug interaction of single oral doses of midazolam and caffeine with 10 and 25 mg obeticholic acid in healthy subjects

Trial Profile

A phase 1 single center, open label, fixed sequence, parallel group study evaluating pharmacokinetic drug-drug interaction of single oral doses of midazolam and caffeine with 10 and 25 mg obeticholic acid in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Obeticholic acid (Primary) ; Caffeine; Midazolam
  • Indications Primary biliary cirrhosis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 28 Aug 2017 New trial record
    • 14 Aug 2017 Results published in the Advances in Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top